On July 31, 2026, Galectin Therapeutics Inc. issued 34,376,167 shares of common stock to Richard E. Uihlein, the Company's Chairman, as part of the conversion of outstanding convertible promissory notes. This event consolidates the Company's outstanding credit facilities into equity
Company Information
Company
GALECTIN THERAPEUTICS INC
Location
Norcross, Georgia, United States
About
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin’s lead drug belapectin (formerly known as GR-MD-02) is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH-related fibrosis.
Fundz sees it the moment GALECTIN THERAPEUTICS INC raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
NorcrossBiotechnologyHealthcareHealth CareTherapeutics